THIS IS THE FACE OF ADVANCED BCC TODAY

Advanced BCCs can develop in difficult-to-treat areas such as the periorbital region, and treatment may result in sequelae such as deformity and loss of vision.[1-4] When the location of the advanced BCC presents treatment challenges...

WHAT'S NEXT FOR THESE PATIENTS?

For More Information: Register Now
http://interactive.genentech.com/content/emedia/view/SkinCancer-Opt-In.view.html?cid=3001HHHSDS

Genentech is investigating the molecular basis of skin cancers such as advanced BCC.

Register now for more information.
http://interactive.genentech.com/content/emedia/view/SkinCancer-Opt-In.view.html?cid=3001HHHSDS

References: 1. Leibovitch I, McNab A, Sullivan T, Davis G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112:717-723. 2. Tildsley J, Diaper C, Herd R. Mohs surgery vs primary excision for eyelid BCCs. Orbit. 2010;29:140-145. 3. Randle HW. Basal cell carcinoma: identification and treatment of the high-risk patient. Dermatol Surg. 1996;22:255-261. 4. García Martín E, Fernández Tirado FJ. Periocular basal cell carcinoma treatment tendencies. Arch Soc Esp Oftalmol. 2010;85:261-262.

To view the Privacy Policy, please copy and paste the URL below into a Web browser:
http://www.gene.com/gene/privacy.html?cid=3001HHHSDS

To view the Terms and Conditions, please copy and paste the URL below into a Web browser:
http://www.gene.com/gene/terms.html?cid=3001HHHSDS

To contact Genentech[R], please copy and paste the URL below into a Web browser:
http://www.gene.com/gene/contact/san-francisco.html?cid=3001HHHSDS

To visit Genentech[R], please copy and paste the URL below into a Web browser:
http://www.gene.com/gene/index.jsp?cid=3001HHHSDS

This e-mail is intended for U.S. healthcare professionals only.

Genentech USA, Inc.
1 DNA Way
South San Francisco, CA
94080-4990

Copyright 2011 Genentech USA, Inc. All rights reserved.

To unsubscribe from the Genentech mailing list, please copy and paste the URL below into a Web browser:
http://interactive.genentech.com/content/emedia/view/SkinCancer-Opt-Out.view.html?cid=3001HHHSDS

HED0000676800